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Healthcare Associated Infection and Antimicrobial Resistance Department, Public Health England, Colindale, London, UKAbstractEscherichia coli is the commonest cause of bacteraemia in England, with an incidence of 50.7 cases per 100 000 population in 2011. We
undertook a large national study to estimate and identify risk factors for 30-day all-cause mortality in E. coli bacteraemia patients. Records
for patients with E. coli bacteraemia reported to the English national mandatory surveillance system between 1 July 2011 and 30 June
2012 were linked to death registrations to determine 30-day all-cause mortality. A multivariable regression model was used to identify
factors associated with 30-day all-cause mortality. There were 5220 deaths in 28 616 E. coli bacteraemia patients, a mortality rate of
18.2% (95% CI 17.8–18.7%). Three-quarters of deaths occurred within 14 days of specimen collection. Factors independently associated
with increased mortality were: age < 1 year or > 44 years; an underlying respiratory or unknown infection focus; ciproﬂoxacin non-
susceptibility; hospital-onset infection or not being admitted; and bacteraemia occurring in the winter. Female gender and a urogenital
focus were associated with a reduction in mortality. This is the ﬁrst national study of mortality among E. coli bacteraemia patients in
England. Interventions to reduce mortality need to be multifaceted and include both primary and secondary healthcare providers.
Greater awareness of the risk factors for and symptoms of E. coli bacteraemia may prompt earlier diagnosis and treatment. Changes in
antimicrobial resistance patterns need to be monitored for their potential impact on infection and mortality.
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E-mail: Julia.abernethy@phe.gov.ukIntroductionEscherichia coli is the leading cause of bacteraemia in England,
although overall the incidence of bacteraemia in England has
declined in recent years [1]. Voluntary surveillance showed
that E. coli bacteraemia cases more than doubled between
2002 (12 652 cases) and 2011 (26 912 cases); the latter
equates to an incidence of 50.7 cases per 100 000 population
per year (M. Muzyamba, personal communication). Over theown Copyright © 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalsame period a 33% decline in Staphylococcus aureus bacter-
aemia occurred [2].
To more accurately monitor incidence and enhance under-
standing of E. coli bacteraemia epidemiology the Department of
Health in England made reporting of E. coli bacteraemia
mandatory from June 2011. In this surveillance programme,
coordinated by Public Health England, all English National
Health Service (NHS) hospitals must electronically report all
blood cultures that test positive for E. coli via a web-based
system. Data items reported include patient demographics
and clinical features. Reports are made by infection control
staff.
All-cause mortality among bacteraemia patients can be high,
particularly when a resistant strain is the causative organism.
For example, 30-day all-cause mortality among methicillin-
resistant S. aureus (MRSA) bacteraemia patients in EnglandClin Microbiol Infect 2015; 21: 251.e1–251.e8
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S. aureus bacteraemia patients an estimate of 27% has been
reported [4]. Antimicrobial-resistant extended-spectrum
β-lactamase (ESBL) -producing strains of E. coli have also been
associated with increased mortality compared with non-ESBL-
producing strains [5–7]. Published estimates of 30-day all-
cause mortality among E. coli bacteraemia patients vary
dramatically from around 10 to 35% [5–16]. Most of these
estimates were from single-centre studies examining speciﬁc
patient populations; among those studies considering more
representative patient populations, Schlackow et al. [16] stud-
ied patients with E. coli bacteraemia detected in a large English
region and reported 28-day mortality of 17%. In contrast, a
Finnish population study reported mortality in E. coli bacter-
aemia patients of only 8% [17]. A large Canadian study [18]
reported a case fatality rate of 11% for hospital inpatients
with E. coli bacteraemia whereas in Auckland, New Zealand, the
inpatient mortality rate was estimated at 9% [19]. We report
here the use of English mandatory surveillance data linked to
death registrations to determine 30-day all-cause mortality
among a large nationwide data set of patients with E. coli
bacteraemia.MethodsEscherichia coli bacteraemia cases in England were identiﬁed
from all reports made to the national mandatory surveillance
scheme between 1 July 2011 and 30 June 2012. The total
number of patients was determined by identifying multiple ep-
isodes per patient using their NHS number (unique patient
identiﬁer) or where missing, date of birth and hospital number,
and retaining the last episode for analysis.
Mortality outcome (dead or alive) 30 days after specimen
date was ascertained by deterministically linking the manda-
tory bacteraemia surveillance data to Ofﬁce for National
Statistics Death Registrations [20] using NHS number and to
the NHS Spine (centralized repository of patient information)
using NHS number and date of birth; patients were lost to
follow up if they could not be linked to either data set. Thirty-
day all-cause mortality was calculated using all deaths within 30
days of positive specimen collection as the numerator and
patients as the denominator (excluding those lost to follow
up). A population mortality rate (MR) was calculated by
applying the MR for all E. coli bacteraemia patients (i.e. without
omitting those lost to follow up) in the study period and
dividing by the English 2011 population estimate [21]. Antibi-
otic susceptibilities were obtained by linking the mandatory
surveillance data with voluntary reports of antibiotic suscep-
tibility made to Public Health England’s national databaseCrown Copyright © 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalf
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(NHS number, hospital number, date of birth, gender,
encrypted surname). Data were collected on the susceptibility
of E. coli to third-generation cephalosporins (cefotaxime/cef-
tazidime), ciproﬂoxacin and carbapenems (imipenem/
meropenem).
The time of onset of bacteraemia in relation to hospital
admission was calculated as the difference (in days) between
admission and the taking of a positive blood culture. Time of
bacteraemia onset was categorized as blood culture taken: (i)
on admission or day after admission (a proxy for community-
onset infection); (ii) 2–6 days after admission; (iii) 7 days or
more after admission (both (ii) and (iii) are a proxy for
healthcare-onset infection); (iv) from a non-admitted patient.
The underlying foci of infection believed to have led to bac-
teraemia were grouped as follows: respiratory, urogenital
tract, unknown and other (bone and joint, central nervous
system, gastrointestinal, hepatobiliary, indwelling intravascular
device, no clinical signs of bacteraemia, and skin/soft-tissue
infection). For assessment of seasonal variation in bacter-
aemia, season was deﬁned as spring (March–May), summer
(June–August), autumn (September–November) or winter
(December–February).
Identiﬁcation of patients with mention of sepsis/septicaemia/
bacteraemia or E. coli (or all) as the cause of death was un-
dertaken by examining the free text cause of death ﬁelds of
death registration certiﬁcates for patients who linked to the
Ofﬁce for National Statistics data set and died within 30 days of
specimen collection.
Multivariable logistic regression was used to examine the
independent effects of factors identiﬁed from the literature, and
a priori confounders (age and sex) as likely to be associated with
30-day all-cause mortality. Patients with missing outcome or
exposure variables were excluded. A random effects term was
included to control for possible similarity of patients within
each hospital in terms of mortality experience and case mix.
Crude and adjusted odds ratios (aOR) and 95% CIs were
determined. A priori determined interaction between underlying
focus of infection and timing of bacteraemia onset (community
versus hospital-onset only) was examined once the ﬁnal model
was built because of the low power of interaction tests. A
sensitivity analysis examining the impact of missing outcome on
the main effects was undertaken in separate models by coding
all cases with missing outcome to ‘alive’ or ‘dead’ and leaving
the rest of the ﬁnal model unchanged. A ﬁnal discrete model to
examine the effect of non-susceptibility to any of three anti-
microbial classes (ciproﬂoxacin, third-generation cephalospo-
rins or carbapenems) on mortality was built. All data
management and statistical analyses were performed in STATA
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July 2011 to June 2012, representing 30 166 patients. Of these
patients, four were excluded because of inconsistent dates of
specimen/death and 1546 were lost to follow up. The remaining
28 616 patients were included in the mortality analysis. A
further 12 484 patients were excluded from the regression
analysis due to missing exposure data.
Of the 28 616 patients followed up, 13 398 (46.8%) were
men and 15 218 (53.2%) were women (Table 1). Almost 90% of
reports were in patients aged 45 years or more. Among pa-
tients with admission information, 72.8% (20 781/28 542) had
community-onset infections as deﬁned here. Where underlying
focus was reported (n = 24 918; 87.1%), the urogenital tract
predominated (n = 13 062; 52.4%), followed by ‘other’
(n = 6612; 26.5%), unknown (n = 4332; 17.3%) and respiratory
tract (n = 912; 3.7%). By timing of onset, the urogenital tract
still predominated, although the relative proportion declined
from 55.3% of community-onset infections to 45.1% among
those with healthcare-onset bacteraemia (Table 2). In all,
18 479, 18 256 and 20 475 patients had cephalosporin, carba-
penem and ciproﬂoxacin susceptibility results available,
respectively, of which 1838 (10.0%), 24 (0.13%) and 3647TABLE 1. Description of study patients and 30-day all-cause morta
All patients
n
Total 28 616
Gender Male 13 398
Female 15 218
Age at diagnosis 0 < 1 year 447
1 < 45 years 2607
45 < 85 years 19 363
85 years 6199
Number of previous episodes 0 27 103
1 1513
Timing of bacteraemia onset Community onset:
(0–1 day after admission) 20 781
Healthcare onset:
(2–6 days after admission) 2350
7 days after admission 4689
Not admitted 722
Missing 74
Season of specimen collection Spring 7276
Summer 7424
Autumn 7126
Winter 6790
Underlying focus of infection Other 6612
Respiratory 912
Urogenital tract 13 062
Unknown 4332
Missing 3698
Cephalosporin susceptibilitya S 16 641
NS 1838
Not tested/missing 10 137
Carbapenem susceptibilitya S 18 232
NS 24
Not tested/missing 10 360
Ciproﬂoxacin susceptibilitya S 16 828
NS 3647
Not tested/missing 8141
aS, susceptible; NS, non-susceptible
Crown Copyright © 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalf(17.8%) were non-susceptible to those agents. Cephalosporin
and ciproﬂoxacin non-susceptibility increased with increasing
timing of onset (Table 2). Most (17/24) carbapenem non-
susceptible isolates were from patients diagnosed around the
time of admission.
Thirty-day all-cause mortality was 18.2% (17.8–18.7%)
(5220/28 616) (Table 1). This equates to an MR of 10.34 per
100 000 population. Thirty percent (1581) of patients who
died, did so on or the day after specimen collection (Fig. 1),
increasing to 58.4% (3047) by 7 days and to 76.3% (3984) by 14
days. A peak in mortality was still observed on or the day after
specimen collection upon stratiﬁcation by timing of bacteraemia
onset (Fig. 2). Among the 5220 deaths, sepsis/septicaemia/
bacteraemia or E. coli was mentioned as the cause of death for
2007 patients (38% of all 30-day deaths).
The lowest mortality was observed among those aged be-
tween 1 and 45 years (140 deaths; MR 5.4%, 95% CI 4.5–6.3%)
(Table 1). Fatality among men (2797 deaths; MR 20.9%, 95% CI
20.1–21.5%) was higher than among women (2423 deaths; MR
15.9%, 95% CI 15.3–16.5%). Mortality among patients with an
underlying respiratory focus of infection was 34.0% (95% CI
30.9–37.2%; 310 deaths), 25.9% (95% CI 24.6–27.2%; 1112
deaths) in those with an unknown focus and 13.2% (95% CI
12.6–13.8%; 1719 deaths) in patients with a urogenital focus.lity for patients with complete mortality follow-up details
Patients who died within 30 days of specimen collection
Number of deaths Mortality rate (95% CI)
5220 18.2 (17.8–18.7)
2797 20.9 (20.1–21.5)
2423 15.9 (15.3–16.5)
59 13.2 (10.2–16.7)
140 5.4 (4.5–6.3)
3459 17.9 (17.3–18.4)
1562 25.2 (24.1–26.3)
4888 18.0 (17.6–18.5)
332 21.9 (19.9–24.1)
3179 15.3 (14.8–15.8)
571 24.3 (22.6–26.1)
1271 27.1 (25.8–28.4)
177 24.5 (21.4–27.8)
22 29.7 (19.7–41.5)
1300 17.9 (17.0–18.8)
1289 17.4 (16.5–18.2)
1310 18.4 (17.5–19.3)
1312 19.5 (18.4–20.3)
1360 20.6 (19.6–21.6)
310 34.0 (30.9–37.2)
1719 13.2 (12.6–13.8)
1122 25.9 (24.6–27.2)
709 19.2 (17.9–20.5)
2911 17.5 (16.9–18.1)
392 21.3 (19.4–23.2)
1917 18.9 (18.2–19.7)
3304 18.1 (17.6–18.7)
6 25.0 (9.8–46.7)
1910 18.4 (17.7–19.2)
2853 17.0 (16.4–17.5)
797 21.9 (20.5–23.2)
1570 19.3 (18.4–20.2)
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TABLE 2. Underlying focus of infection and antibiotic susceptibilities in relation to time of Escherichia coli bacteraemia onset in all
patients
Timing of bacteraemia onseta
0–1 day after
admission
2–6 days after
admission
7 or more days
after admission Not admitted Total
n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI)
Underlying focus
of infectionb
Other 4706 24.5 (23.9–25.2) 784 36.2 (34.1–38.2) 1351 31.6 (30.2–33.0) 109 18.3 (15.2–21.6) 6950 26.5 (26.0–27.0)
Respiratory 654 3.4 (3.2–3.7) 65 3.0 (2.3–3.8) 214 5.0 (4.4–5.7) 17 2.9 (1.7–4.5) 950 3.6 (3.4–3.9)
Urinary tract 10 598 55.3 (54.6–56.0) 924 42.6 (40.5–44.7) 1929 45.1 (43.6–46.6) 297 49.7 (45.7–53.8) 13 748 52.4 (51.8–53.0)
Unknown 3216 16.8 (16.2–17.3) 395 18.2 (16.6–19.9) 783 18.3 (17.2–19.5) 174 29.2 (25.5–33.0) 4568 17.4 (17.0–17.9)
Total 19 174 100 2168 100 4277 100 597 100 26 216 100
Cephalosporin
susceptibilityc,d
S 12 919 91.1 (90.7–91.6) 1424 88.8 (87.2–90.3) 2594 85.3 (84.0–86.5) 488 91.4 (88.7–93.6) 17 425 90.0 (89.6–90.5)
NS 1257 8.9 (8.4, –9.3) 179 11.2 (9.7–12.8) 447 14.7 (13.5–16.0) 46 8.6 (6.4–11.3) 1929 10.0 (9.5–10.4)
Total 14 176 100 1603 100 3041 100 534 100 19 354 100
Carbapenem
susceptibilityd, e
S 13 965 99.9 (99.8–99.9) 1585 99.8 (99.4–99.9) 3040 99.9 (99.7–100) 513 100 19 103 99.9 (99.8–99.9)
NS 17 0.1 (0.07–0.19) 4 0.25 (0.06–0.6) 3 0.1 (0.02– ,0.3) 0 0 24 0.13 (0.08–0.1)
Total 13 982 100 1589 100 3043 100 513 100 19 127 100
Ciproﬂoxacin
susceptibility d,f
S 13 155 83.3 (82.7–83.9) 1429 81.01 (79.1–82.8) 2544 76.9 (75.4–78.3) 487 83.4 (80.1–86.3) 17 615 82.1 (81.6–82.6)
NS 2637 16.7 (16.1–17.3) 335 19.0 (17.2–20.9) 765 23.1 (21.7–24.6) 97 16.6 (13.7–19.9) 3834 17.9 (17.4–18.4)
Total 15 792 100 1764 100 3309 100 584 100 21 449 100
aExcludes 76 cases with missing timing of onset.
bAdditionally excludes 3870 cases with missing bacteraemia focus of infection.
cS, susceptible; NS, non-susceptible.
dAdditionally excludes 10 732 cases with not tested/missing cephalosporin susceptibilities.
eAdditionally excludes 10 959 cases with not tested/missing carbapenem susceptibilities.
fAdditionally excludes 8637 cases with not tested/missing ciproﬂoxacin susceptibilities.
251.e4 Clinical Microbiology and Infection, Volume 21 Number 3, March 2015 CMIPatients with community-onset infection had lower mortality
(MR 15.3, 95% CI 14.8–15.8%; 3179 deaths) compared with
other onset categories. Mortality was slightly higher in those
with E. coli bacteraemia that was non-susceptible to carbape-
nems, cephalosporins or ciproﬂoxacin (MR range from 21.3 for
cephalosporins to 25.0% for carbapenems), compared with
those whose infection was susceptible to these antibiotics (MR
range from 17.0 for ciproﬂoxacin to 18.1% for carbapenems).
Patients with a previous E. coli bacteraemia episode had a higher
MR compared with those without (21.9%, 95% CI 19.9–24.1%
versus 18.0%, 95% CI 17.6–18.5%, respectively). By season there
was a slight increase in mortality in autumn and winter (Table 1).
Age showed the strongest association with 30-day mortality
(Table 3). Compared with the baseline age group individualsCrown Copyright © 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalf
CMI, 21, 251.e1–251.e8aged  85 years had a six-fold increase in the odds of death
(aOR 5.91; 95% CI 4.61–7.58), whereas those aged 45 to < 84
years had a three-fold increase (aOR 3.42; 95% CI 2.69–4.35);
those aged 0–1 year had a smaller increase (aOR 1.66; 95% CI
1.01–2.71). Respiratory (aOR 1.84; 95% CI 1.51–2.23) or
unknown (aOR 1.45; 95% CI 1.28–1.65) foci were associated
with an increase in mortality whereas a urinary focus (aOR
0.57; 95% CI 0.51–0.63) was associated with a reduction,
compared with ‘other’ foci. Compared with patients with
community-onset infection, patients with specimens collected
2–6 days (aOR 1.73; 95% CI 1.50–1.99) or 7 or more days
(aOR 2.00; 95% CI 1.80–2.22) after admission had an increased
risk of death, as did non-admitted patients (aOR 2.03; 95% CI
1.58–2.62). Cephalosporin non-susceptibility was associatedFIG. 1. Time to death (all-cause mortality),
in days after positive blood culture, in pa-
tients who died within 30 days of a blood
culture being taken that grew Escherichia coli.
of European Society of Clinical Microbiology and Infectious Diseases. All rights reserved,
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FIG. 2. Time to death (all-cause mortality), in days after positive blood culture, in patients who died within 30 days of a blood culture being taken that
grew E. coli in relation to timing of bacteraemia onset. Sixty-nine patients were not admitted but died one or more days after specimen collection. This
may be due to many factors such as inaccurate data entry or patients self-discharging after specimen collection.
TABLE 3. Crude and adjusteda analysis of factors associated with 30-day all-cause mortality in patients with Escherichia coli
bacteraemia
Factor
Crude and adjusted odds ratios of risk factors associated with 30-day all-cause mortality
Crude OR 95% CI p-value Adjusted OR 95% CI p-value
Age at diagnosis 0 < 1 year 2.70 (1.94–3.71) <0.0001 1.66 (1.01–2.71) 0.045
1 < 45 years 1 1
45 < 85 years 3.83 (3.22–4.57) <0.0001 3.42 (2.69–4.35) <0.0001
85 years 5.94 (4.94–7.14) <0.0001 5.91 (4.61–7.58) <0.0001
Gender Male 1 1
Female 0.72 (0.68–0.76) <0.0001 0.85 (0.78–0.92) <0.0001
Number of previous
episodes
0 1
1 1.28 (1.13–1.45) 0.02 Not included
Timing of bacteraemia
onset
Community onset:
0–2 days after admission
1 1
Healthcare onset:
2–6 days after admission
1.43 (1.38–1.48) <0.0001 1.73 (1.51–1.99) <0.0001
7 days after admission 2.06 (1.91–2.22) <0.0001 2.00 (1.80–2.22) <0.0001
Not admitted 1.80 (1.51–2.14) <0.0001 2.03 (1.58–2.62) <0.0001
Season of specimen
collection
Spring 1 1
Summer 0.97 (0.89–1.05) 0.50 1.01 (0.89–1.14) 0.893
Autumn 1.04 (0.95–1.13) 0.96 1.06 (0.94–1.20) 0.309
Winter 1.11 (1.02–1.21) 0.01 1.19 (1.06–1.34) 0.004
Underlying focus of
infection
Other 1 1
Respiratory 1.99 (1.71–2.31) <0.0001 1.84 (1.51–2.23) <0.0001
Urogenital tract 0.58 (0.54–0.63) <0.0001 0.57 (0.51–0.63) <0.0001
Unknown 1.35 (1.23–1.48) <0.0001 1.45 (1.28–1.65) <0.0001
Cephalosporin
susceptibilityb
S 1 1
NS 1.28 (1.14–1.44) <0.0001 1.08 (0.93–1.26) 0.303
Carbapenem
susceptibilityb
S 1
NS 1.51 (0.60–3.80) 0.62 Not included
Ciproﬂoxacin
susceptibilityb
S 1 1
NS 1.37 (1.25–1.50) <0.0001 1.30 (1.15–1.46) <0.0001
aFinal model includes risk factors identiﬁed from the literature and age and gender as a priori risk factors. Other variables were only included if they changed the effect of the main risk
factors and were associated in the crude analysis. Adjusted ORs are adjusted for all other risk factors in the ﬁnal model.
bS, susceptible; NS, non-susceptible.
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1.14–1.44) but not in the adjusted model (aOR 1.08; 95% CI
0.93–1.26). Ciproﬂoxacin non-susceptibility increased the odds
of death (aOR 1.30; 95% CI 1.15–1.46). As there was no evi-
dence for crude association with carbapenem non-susceptibility
(OR 1.51; 95% CI 0.60–3.80) it was not included in the adjusted
model. Female gender was associated with a small reduction
(aOR 0.85; 95% CI 0.78–0.92) in mortality compared with male
gender, whereas the winter season was associated with a small
increase in mortality (aOR 1.19; 95% CI 1.06–1.34).
Although there was statistical evidence supporting interactions
between underlying focus of infection and timing of bacteraemia
onset (p 0.0361; not shown) it is not presented because it did not
alter the ﬁndings reported above for timing of onset and focus.
The main effects in the ﬁnal model remained stable when cases
with missing outcome information were coded to either being
alive or dead (see Supporting information, Table S1). The second
model combining non-susceptibilities to all three antimicrobials
showed a 30% increase in the odds of death (aOR 1.33;
1.21–1.46) with other effect estimates remaining stable
compared with the ﬁrst model (data not shown).DiscussionWe estimated a 30-day all-cause mortality of 18.2% among E. coli
bacteraemia patients in England with one-third of deaths
occurring on the day or day after the ﬁrst positive blood culture.
We identiﬁed several independent factors for 30-day mortality:
younger (0 to < 1 year) and older (> 44 years) age; a respiratory
or unknown underlying infection focus; hospital-onset infection
or not being admitted; ciproﬂoxacin non-susceptibility, and
winter season. An underlying urogenital focus of infection and
female gender were associated with reduced mortality.
The 30-day all-cause mortality reported here is consistent
with a recent English regional analysis that reported mortality of
17% [16], but higher than a Finnish population-based study (8%)
[17]. The reasons for this are not clear but could include factors
relating to the population experiencing E. coli bacteraemia, such
as relative levels of co-morbidities. Two other population-based
studies [18,19] reported mortality rates in line with the Finnish
estimates; however as these examined inpatient mortality they
may underestimate mortality compared with the present study,
which is not limited to inpatients.
The English estimates fall towards the bottom of the range of
published E. coli bacteraemia 30-day all-cause mortality esti-
mates (10–35%) [5–16] although comparability is minimal
because of many published studies being based on single centres
and/or speciﬁc patient populations, which may have speciﬁc
mortality experiences.Crown Copyright © 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalf
CMI, 21, 251.e1–251.e8Compared with MRSA bacteraemia in England, an infection
that often receives considerable attention and where similar
published mortality data are available, mortality in our study is
lower (18.2% versus 38% [3], respectively). However, the
comparable estimated population death rate is doubled because
of the higher incidence of E. coli versus MRSA bacteraemia
(10.34 versus 5.51 per 100 000, respectively). Although there
are caveats around this comparison in that the time periods
covered and methodologies differ slightly (e.g. the MRSA study
was based on voluntary reports while we have used mandatory
surveillance data for E. coli) it nonetheless seems reasonable to
conclude that although MRSA bacteraemia may have a higher
mortality rate, the overall clinical impact of E. coli bacteraemia
on the population is considerably greater. We have not
examined attributable 30-day mortality because of its potential
biases in recording cause of death; however, for 38% of patients
who died, the death registration mentioned one or more of
sepsis/septicaemia/bacteraemia or E. coli.
The underlying focus of infection had a signiﬁcant impact on
mortality. The increase in mortality associated with a respiratory
or unknown focus compared with the reduction seen for the
urogenital tract is consistent with published studies [24]. An
underlying respiratory focus may be associated with several risk
factors for increased mortality including co-morbidities [5–7]
and a greater sepsis severity score [6,9]. Conversely, urogeni-
tal tract-related bacteraemias may be typically found in other-
wise well patients and have a readily modiﬁable source of
infection, such as a urinary catheter. This suggests that for res-
olution of a bloodstream infection, any underlying cause/source
of infection must be adequately treated to prevent the patients’
blood being re-seeded with bacteria. Paradoxically, although a
bacteraemia with an underlying urogenital tract focus has a
lower associated mortality, at a population level the high prev-
alence of this focus means that it is associated with the largest
number of deaths. Hence, to achieve signiﬁcant reduction in
morbidity and mortality caused by E. coli bacteraemia, potential
interventions aimed at preventing urinary tract infections (UTIs)
or their progression to the bloodstream merit further investi-
gation. Devices provide a portal of entry for bacteria into the
urinary tract, so device-related UTI-based interventions are an
obvious target, such as better urinary catheter management,
improved design and appropriate usage. In England, guidance on
diagnosis and treatment of UTIs [25] and catheter care [26]
exist, but uptake levels are unclear. Many patients are diag-
nosed with and treated for UTI in primary care [27]; however,
we found that the urogenital tract was also the most common
infection focus for healthcare-onset E. coli bacteraemia. Cathe-
terized patients commonly reside in the community, with cath-
eters that were inserted in hospital [28]. Hence UTI-based
interventions should be considered in both the community andof European Society of Clinical Microbiology and Infectious Diseases. All rights reserved,
CMI Abernethy et al. Mortality in E. coli bacteraemia patients in England 251.e7hospital settings with communication essential to ensure conti-
nuity of care, e.g. if a patient is discharged from hospital with a
urinary catheter, the community-care providers should know
why the device is in place and manage appropriately.
The impact of timing of onset on mortality is complex,
reﬂecting several factors such as increased co-morbidities and
greater chance of acquisition of a resistant healthcare-associated E
coli strain for hospitalized patients. Although numerically the
greatest number of cases and deaths were among patients with
community-onset infection, mortality was highest in patients with
healthcare-onset bacteraemia. Such infections are most likely to
be healthcare-associated and more readily amenable to hospital-
based interventions. However, regardless of timing of onset,
most deaths occurred soon after specimen collection, indicating
late diagnosis of E. coli bacteraemia with limited opportunity for
treatment due to advanced disease progression. To mitigate this,
underlying infections need to be diagnosed and treated before
bacteraemia development, coupled with prompt diagnosis and
treatment of bacteraemias, especially in high-risk groups.
There is evidence for seasonality in the incidence of E. coli
bacteraemia with a peak in the summer months [1] and in
mortality associated with S. aureus bacteraemia where there
was an increase in deaths in winter [3]. We found a small in-
dependent effect of winter season on mortality, based on the
season of specimen collection. This may reﬂect seasonality in
co-morbidities, or as hypothesized for MRSA bacteraemia, in
bed occupancy [29] among other factors.
There is considerable attention on antimicrobial resistance in
England [30], therefore ﬁndings relating to this factor in the pre-
sent study are of interest. Although ESBL-producing E. coli have
been associated with increased mortality in bacteraemia [5–7], in
this study, cephalosporin non-susceptibility, which probably re-
ﬂects ESBL production in most isolates, showed no effect in the
adjusted model although an effect was noted with ciproﬂoxacin
non-susceptibility. Further work is required to understand this,
such as trying to correlate antibiotic therapy with patient
outcome, and to examine the associationwith antibiotic resistance
and E. coli strains and virulence factors. Nonetheless, although the
impact of ciproﬂoxacin non-susceptibility onmortality is relatively
small it is important as non-susceptibility levels in England, Wales
and Northern Ireland in E. coli bloodstream isolates are high at
around 19% [31]. We further found that the proportion of
cephalosporin and ciproﬂoxacin non-susceptible E. coli isolates
was higher in patients with healthcare-onset versus community-
onset infection. Notably mortality among patients with carbape-
nem non-susceptible E. coli was high (25.0%; 9.8–46.7). This was
not however statistically signiﬁcant, possibly reﬂecting the small
number of patients with carbapenem-resistant E. coli; a signiﬁcant
effect may have been found with a larger sample size. Carbape-
nems are second-line antibiotics used to treat severe infectionsCrown Copyright © 2015 Clinical Microbiology and Infection published by Elsevier Ltd on behalfand an increase in non-susceptibility may dramatically increase
mortality in affected patients. Overall, the impact of having a non-
susceptible E. coli bacteraemia in our study increased the risk of
mortality by 30%. Inappropriate prescribing will increase antibiotic
selection pressure and the prevalence of resistance limiting
effective treatment options, so impacting on mortality associated
with many infections, not only E. coli bacteraemia.
There are limitations to the present study. Not all patients
were followed up and the adjusted regression model had sub-
stantial missing exposure information with the regression
analysis using only 57% (16 132/28 616) of patients with
outcome data. Although this may introduce bias, the direction
of which is not possible to determine, the size of the analysed
data set does give some conﬁdence in the effect estimates.
Additionally, not all variables of interest were available (e.g. co-
morbidities, antimicrobial prescribing, catheter usage) and
further work is required to gain greater insight into these in-
fections and to identify areas for intervention.
Our data suggest that interventions to reduce mortality
among E. coli bacteraemia patients should involve primary and
secondary care. There needs to be effective treatment of un-
derlying infections and earlier diagnosis and treatment for E. coli
bacteraemia as one-third of patients die around the time that
positive blood cultures are taken. Although the impact of
antimicrobial resistance on mortality was apparent, further
study is required to look at the association between patient-
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